CytomX Therapeutics, Inc. (NASDAQ:CTMX), today announced that on February 3, 2020, the Company granted its recently appointed senior vice president and chief medical officer, Alison L. Hannah, M.D., an option to purchase 250,000 shares of the Company’s common stock at an exercise price per share equal to $7.71
February 7, 2020
· 2 min read